---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017184"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T01:04:38.919200+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q1 net loss $66.7M ($1.53/share); cash $473.5M; pipeline advances

## Summary
- Cash, equivalents and marketable securities $473.5M as of Mar 31, 2023; runway into 2025.
- Revenue $19.1M, down from $22.2M YoY mainly due to lower Zolgensma royalties ($16.1M vs $21.5M).
- Net loss $66.7M ($1.53 per share) vs $76.7M ($1.79) YoY; R&D spend up to $58.5M.
- Subretinal ABBV-RGX-314 pivotal trials expanded; regulatory submissions expected late 2025 to H1 2026.
- RGX-202 Duchenne trial on track for initial data H2 2023; RGX-121 BLA filing planned in 2024.

## SEC filing metadata
- accession: 0000950170-23-017184
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017023017184/0000950170-23-017184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017023017184/rgnx-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017184
- JSON: https://secwatch.observer/filing/0000950170-23-017184.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017184.txt

## Key facts
- Earnings Releases
  REGENXBIO Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 3, 2023, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000095017023017184/0000950170-23-017184-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.